Developed by Zoetis, Apoquel is a prescription-only Janus kinase (JAK) inhibitor approved for veterinary use that targets the itch and inflammation pathway.
Ben Hurst, Product Manager, Zoetis UK said: "Atopic dermatitis is one of the most common allergies in dogs, affecting approximately 10% of the dog population1.
"Itching caused by an allergic skin disease can impact the quality of life for both the dog and its owner unless they are controlled with effective management.
"Apoquel chewable tablets now offer a new, convenient and palatable solution for dog owners."
Apoquel chewable tablets are administered twice daily for up to 14 days (at 0.4 to 0.6 mg/kg), then once daily for maintenance therapy.
Zoetis says marketing authorisation for the EU market is expected later this year following the Committee for Medicinal Products for Veterinary Use (CVMP) positive opinion received on 7th October 2021.
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.
Publishing Editor: Arlo Guthrie
Clinical Editor: Alasdair Hotston Moore MA VetMB CertSAC CertVR CertSAS FRCVS
Facebook | Linkedin | Instagram | Twitter
Learn more about advertising on VetSurgeon.org
VetSurgeon Jobs is the place to advertise and find permanent and locum jobs for veterinary surgeons in England | Scotland | Wales | Ireland and Worldwide. Follow VS Jobs on Facebook | Linkedin | Twitter
Veterinary Anaesthesia | Veterinary Cardiology | Veterinary Dentistry | Veterinary Dermatology | Diagnostic Imaging | Veterinary ECC | Equine Medicine & Surgery | Farm Animal Medicine & Surgery | Veterinary Medicine | Veterinary Neurology Veterinary Oncology | Veterinary Ophthalmology | Veterinary Orthopaedics | Pathology/Cytology | Veterinary Surgery